z-logo
open-access-imgOpen Access
Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers
Author(s) -
Andrew Nicholls,
Raúl Harris-Collazo,
Michael Huang,
Yun Hardiman,
Richard J. Jones,
Luigi Moro
Publication year - 2013
Publication title -
journal of international medical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.421
H-Index - 57
eISSN - 1473-2300
pISSN - 0300-0605
DOI - 10.1177/0300060513476588
Subject(s) - pharmacokinetics , medicine , bioavailability , crossover study , budesonide , bioequivalence , confidence interval , pharmacology , area under the curve , gastroenterology , chromatography , corticosteroid , chemistry , alternative medicine , pathology , placebo
Objective To compare the pharmacokinetics of the extended-release MMX® formulation of budesonide (Uceris®) with that of Entocort® EC, an extended (controlled ileal) release formulation of budesonide.Methods Using an open-label, randomized, three-period crossover, Latin square design, healthy male or female volunteers received single doses of 6 mg Uceris®, 9 mg Uceris® or 9 mg Entocort® EC. Standard pharmacokinetic parameters were assessed.Results The study included 12 subjects. The 9 mg Uceris® and 9 mg Entocort® EC formulations had comparable area under the concentration–time curve (AUC) data, but 9 mg Uceris® had a notably longer time to first appearance in plasma (median T lag , 6 h versus 1 h, respectively), and a delayed time to maximum concentration (median T max , 15 h versus 5 h, respectively) compared with 9 mg Entocort® EC. The ratio of log-transformed AUC 0–last (Uceris®/Entocort® EC) was 91% (90% confidence interval [CI] 77%, 108%) and the corresponding maximum concentration ratio was 79% (90% CI 63%, 100%).Conclusion Uceris was associated with a similar extent (AUC) of systemic exposure to budesonide compared with that following Entocort. However, for Uceris, the pharmacokinetic profile was delayed, a pattern consistent with greater colonic delivery of the active substance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here